Question follow-through · 15595
Trastuzumab Deruxtecan
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential impact of NICE's severity modifier on the availability of Enhertu for patients with secondary breast cancer.
About this written question
A written question asks a government minister for information in writing. Parliament publishes the question and any answer.
- Answering body
- Department of Health and Social Care
- Tabled
- 2 Jul 2026
- Target answer date
- 6 Jul 2026
- Answer
- 8 Jul 2026 · 6 calendar days after tabling
Elapsed calendar days describe the record timeline, not whether Parliament considers an answer on time.
Votes on this topic
- Terminally Ill Adults (End of Life) Bill: Second Reading · 11 Sept 2026
- Health Bill: Report Stage: Amendment 1 · 8 Sept 2026
- Health Bill: Report Stage: New Clause 143 · 8 Sept 2026
These Commons divisions share a topic label. The question did not necessarily lead to a vote.
Recorded timeline
2 Jul 2026
Question tabled
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential impact of NICE's severity modifier on the availability of Enhertu for patients with secondary breast cancer.
6 Jul 2026
Target answer date
Date supplied by the official written-questions record.
8 Jul 2026
Answer published
The National Institute for Health and Care Excellence (NICE) considered the impact of its severity modifier as part of its appraisal of Enhertu for HER2-low metastatic breast cancer. However, even with the severity weighting applied, NICE concluded that t...
Official data retrieved 28 Sept 2026.
Later records
Possible follow-up questions
Strong links require the same MP, department and exact heading. Other same-department questions are shown as unreviewed candidates, not as confirmed follow-ups. No debate link is asserted unless a stable source relationship exists.
No later same-department questions indexed.
This is an absence in covered public data, not evidence that no follow-up occurred elsewhere.